{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:33:41Z","timestamp":1790804021069,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","rheumatic.theclinics.com","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rdc.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T19:17:54Z","timestamp":1713986274000},"page":"291-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune Checkpoint Inhibitor-induced Sicca Syndrome"],"prefix":"10.1016","volume":"50","author":[{"given":"Samuel","family":"Bitoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Gosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakiba","family":"Belkhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lazure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.rdc.2024.02.004_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A\u00a0guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.004_bib2","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.rdc.2024.02.004_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.004_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"28","author":"Harris","year":"2022","journal-title":"Oral Dis"},{"issue":"10027","key":"10.1016\/j.rdc.2024.02.004_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.rdc.2024.02.004_bib6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2024.02.004_bib7","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncol"},{"issue":"9","key":"10.1016\/j.rdc.2024.02.004_bib8","doi-asserted-by":"crossref","first-page":"102892","DOI":"10.1016\/j.autrev.2021.102892","article-title":"Tumors, tumor therapies, autoimmunity and the eye","volume":"20","author":"Wildner","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2024.02.004_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1\/PD-L1 Anticancer Immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.004_bib10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"issue":"23","key":"10.1016\/j.rdc.2024.02.004_bib11","first-page":"00134","article-title":"Ocular surface toxicities associated with modern anticancer therapies","volume":"S0039-6257","author":"Boucher","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.rdc.2024.02.004_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"Ocul Surf"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.004_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/08820538.2023.2204931","article-title":"Real Life Impact of Dry Eye Disease","volume":"38","author":"Cutrupi","year":"2023","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.004_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/bjophthalmol-2020-317473","article-title":"Assessment of patient burden from dry eye disease using a combination of five visual analogue scales and a radar graph: a pilot study of the PENTASCORE","volume":"106","author":"Labetoulle","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.004_bib15","doi-asserted-by":"crossref","first-page":"e067007","DOI":"10.1136\/bmjopen-2022-067007","article-title":"Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey","volume":"13","author":"Boboridis","year":"2023","journal-title":"BMJ Open"},{"issue":"Suppl 118","key":"10.1016\/j.rdc.2024.02.004_bib16","first-page":"114","article-title":"Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.004_bib17","doi-asserted-by":"crossref","first-page":"105426","DOI":"10.1016\/j.jbspin.2022.105426","article-title":"Associations between ocular and extra-ocular assessment in primary Sj\u00f6gren\u2019s syndrome","volume":"89","author":"Da Cunha","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"9","key":"10.1016\/j.rdc.2024.02.004_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2024.02.004_bib19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2024.02.004_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren\u2019s syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.rdc.2024.02.004_bib21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fonc.2020.00420","article-title":"Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor","volume":"10","author":"Pringle","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.rdc.2024.02.004_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.004_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.02.004_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.rdc.2024.02.004_bib25","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.004_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.oraloncology.2007.01.015","article-title":"Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction","volume":"44","author":"Jensen","year":"2008","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.004_bib27","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/s41598-020-59078-0","article-title":"Patients with non-Sj\u00f6gren\u2019s sicca report poorer general and oral health-related quality of life than patients with Sj\u00f6gren\u2019s syndrome: a cross-sectional study","volume":"10","author":"Tashbayev","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.rdc.2024.02.004_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajo.2020.05.043","article-title":"Ocular Manifestations and Burden Related to Sj\u00f6gren Syndrome: Results of a Patient Survey","volume":"219","author":"Saldanha","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.rdc.2024.02.004_bib29","first-page":"1259","article-title":"Validation of the Sicca Symptoms Inventory for clinical studies of Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Bowman","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2024.02.004_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/rheumatology\/ken426","article-title":"Patient-reported outcomes in primary Sjogren\u2019s syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort--Sicca Symptoms Inventory","volume":"48","author":"Bowman","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2024.02.004_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.004_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/kev385","article-title":"Is salivary gland ultrasonography a useful tool in Sj\u00f6gren\u2019s syndrome? A systematic review","volume":"55","author":"Jousse-Joulin","year":"2016","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.004_bib33","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/cancers14030792","article-title":"Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases","volume":"14","author":"Yura","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.rdc.2024.02.004_bib34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","article-title":"Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs","volume":"108","author":"Guidera","year":"2001","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.rdc.2024.02.004_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/bjophthalmol-2019-314859","article-title":"Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial","volume":"104","author":"Campos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.rdc.2024.02.004_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtos.2021.09.003","article-title":"Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses","volume":"23","author":"Wang","year":"2022","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.rdc.2024.02.004_bib37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/08820538.2021.1966059","article-title":"Systemic Immunosuppression in Cornea and Ocular Surface Disorders: A Ready Reckoner for Ophthalmologists","volume":"37","author":"Kate","year":"2022","journal-title":"Semin Ophthalmol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T19:54:55Z","timestamp":1713988495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0889857X24000115"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.02.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor-induced Sicca Syndrome","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}